[go: up one dir, main page]

AR124856A2 - Proceso para preparar un compuesto intermediario para la síntesis de compuestos de (ciclopentil[d]pirimidin-4-il)piperazina - Google Patents

Proceso para preparar un compuesto intermediario para la síntesis de compuestos de (ciclopentil[d]pirimidin-4-il)piperazina

Info

Publication number
AR124856A2
AR124856A2 ARP220100275A ARP220100275A AR124856A2 AR 124856 A2 AR124856 A2 AR 124856A2 AR P220100275 A ARP220100275 A AR P220100275A AR P220100275 A ARP220100275 A AR P220100275A AR 124856 A2 AR124856 A2 AR 124856A2
Authority
AR
Argentina
Prior art keywords
pyrimidin
synthesis
cyclopentyl
preparing
intermediate compound
Prior art date
Application number
ARP220100275A
Other languages
English (en)
Inventor
Francis Gosselin
Chong Han
Hans Iding
Reinhard Reents
Scott Savage
Beat Wirz
Original Assignee
Genentech Inc
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc, Hoffmann La Roche filed Critical Genentech Inc
Publication of AR124856A2 publication Critical patent/AR124856A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B57/00—Separation of optically-active compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C253/00—Preparation of carboxylic acid nitriles
    • C07C253/30—Preparation of carboxylic acid nitriles by reactions not involving the formation of cyano groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C253/00—Preparation of carboxylic acid nitriles
    • C07C253/32—Separation; Purification; Stabilisation; Use of additives
    • C07C253/34—Separation; Purification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/19—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms containing cyano groups and carboxyl groups, other than cyano groups, bound to the same saturated acyclic carbon skeleton
    • C07C255/22—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms containing cyano groups and carboxyl groups, other than cyano groups, bound to the same saturated acyclic carbon skeleton containing cyano groups and at least two carboxyl groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/30—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P41/00—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/05—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in nitriles (3.5.5)
    • C12Y305/05001—Nitrilase (3.5.5.1)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La presente descripción se relaciona con un proceso para preparar un compuesto intermediario para la síntesis de compuestos de (ciclopentil[d]pirimidin-4-il)piperazina, y más particularmente para la síntesis de (R)-4-(5-metil-7-oxo-6,7-dihidro-5H-ciclopenta[d]pirimidin-4-il)piperazina y derivados N-protegidos de los mismos, los cuales pueden usarse como un intermediario en la síntesis de Ipatasertib (es decir, (S)-2-(4-clorofenil)-1-(4-((5R,7R)-7-hidroxi-5-metil-6,7-dihidro-5H-ciclopenta[d]pirimidin-4-il)piperazin-1-il)-3-(isopropilamino)-propan-1-ona).
ARP220100275A 2014-09-26 2022-02-11 Proceso para preparar un compuesto intermediario para la síntesis de compuestos de (ciclopentil[d]pirimidin-4-il)piperazina AR124856A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462055893P 2014-09-26 2014-09-26

Publications (1)

Publication Number Publication Date
AR124856A2 true AR124856A2 (es) 2023-05-10

Family

ID=54337353

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP150103093A AR102088A1 (es) 2014-09-26 2015-09-25 Procesos para preparar compuestos de (ciclopentil[d]pirimidin-4-il)piperazina
ARP220100275A AR124856A2 (es) 2014-09-26 2022-02-11 Proceso para preparar un compuesto intermediario para la síntesis de compuestos de (ciclopentil[d]pirimidin-4-il)piperazina

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP150103093A AR102088A1 (es) 2014-09-26 2015-09-25 Procesos para preparar compuestos de (ciclopentil[d]pirimidin-4-il)piperazina

Country Status (21)

Country Link
US (2) US10457648B2 (es)
EP (2) EP3197875B1 (es)
JP (3) JP6676043B2 (es)
KR (1) KR102513869B1 (es)
CN (2) CN107001287B (es)
AR (2) AR102088A1 (es)
AU (2) AU2015320510B2 (es)
BR (1) BR112017005931B1 (es)
CA (2) CA3190507A1 (es)
ES (1) ES2749100T3 (es)
HR (1) HRP20191943T1 (es)
IL (2) IL251313B (es)
MA (1) MA51165A (es)
MX (2) MX380718B (es)
MY (1) MY188699A (es)
PL (1) PL3197875T3 (es)
RU (2) RU2712224C2 (es)
SG (2) SG11201702324QA (es)
SI (1) SI3197875T1 (es)
WO (1) WO2016049414A1 (es)
ZA (1) ZA201702769B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105899492B (zh) 2013-11-15 2021-08-24 豪夫迈·罗氏有限公司 用于制备嘧啶基环戊烷化合物的方法
CA3190507A1 (en) 2014-09-26 2016-03-31 F. Hoffmann-La Roche Ag Processes for preparing (cyclopentyl[d]pyrimidin-4-yl)piperazine compounds
CA3175354A1 (en) * 2020-06-16 2021-12-23 F. Hoffmann-La Roche Ag Process for making hydroxylated cyclopentylpyrimidine compounds
CN112359078A (zh) * 2021-01-12 2021-02-12 凯莱英生命科学技术(天津)有限公司 异丁酸酯类化合物的手性拆分方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1045764A (en) 1912-04-30 1912-11-26 Samuel Allen Guiberson Jr Casing-elevator.
GB9400889D0 (en) 1994-01-18 1994-03-16 Sandoz Ltd Novel compounds
WO2005044819A1 (en) * 2003-10-28 2005-05-19 Schering Corporation Process for preparing substituted 5-amino-pyrazolo-[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines
WO2006052546A2 (en) 2004-11-04 2006-05-18 Neurogen Corporation Pyrazolylmethyl heteroaryl derivatives
TW200630363A (en) * 2004-11-10 2006-09-01 Synta Pharmaceuticals Corp Process for preparing trisubstituted pyrimidine compounds
UA95641C2 (xx) * 2006-07-06 2011-08-25 Эррей Биофарма Инк. Гідроксильовані піримідильні циклопентани як інгібітори акт протеїнкінази$гидроксилированные пиримидильные циклопентаны как ингибиторы акт протеинкиназы
US8063050B2 (en) 2006-07-06 2011-11-22 Array Biopharma Inc. Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors
WO2010002954A1 (en) * 2008-07-02 2010-01-07 Wyeth (2-aryl-7h-pyrrolo[2,3-d]pyrimidin-4-yl)morpholine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses
US8703581B2 (en) 2011-06-15 2014-04-22 Applied Materials, Inc. Water soluble mask for substrate dicing by laser and plasma etch
DE102011080205A1 (de) 2011-08-01 2013-02-07 Bayerische Motoren Werke Aktiengesellschaft Verfahren zur Herstellung faserverstärkter keramischer Formkörper
WO2013068785A1 (en) * 2011-11-09 2013-05-16 Actelion Pharmaceuticals Ltd Indanone and indandione derivatives and heterocyclic analogs
PL2861582T3 (pl) 2012-05-17 2016-11-30 Sposób wytwarzania hydroksylowanych związków cyklopentylopirymidynowych
PL2861583T3 (pl) * 2012-05-17 2016-12-30 Sposób wytwarzania hydroksylowanych związków cyklopentylopirymidyny
SG11201407591PA (en) * 2012-05-17 2015-01-29 Genentech Inc Process of making hydroxylated cyclopentapyrimidine compounds and salts thereof
ES2668477T3 (es) * 2012-05-17 2018-05-18 Genentech, Inc. Proceso de preparación de compuestos de aminoácidos
CN105899492B (zh) 2013-11-15 2021-08-24 豪夫迈·罗氏有限公司 用于制备嘧啶基环戊烷化合物的方法
US9437599B2 (en) * 2014-08-12 2016-09-06 Kabushiki Kaisha Toshiba Nonvolatile semiconductor memory device and method of manufacturing the same
CA3190507A1 (en) * 2014-09-26 2016-03-31 F. Hoffmann-La Roche Ag Processes for preparing (cyclopentyl[d]pyrimidin-4-yl)piperazine compounds
KR102256602B1 (ko) 2017-12-14 2021-05-26 주식회사 엘지에너지솔루션 전압 측정 장치 및 방법

Also Published As

Publication number Publication date
NZ731073A (en) 2021-11-26
AU2019253849A1 (en) 2019-11-14
SI3197875T1 (sl) 2019-12-31
AU2019253849B2 (en) 2020-07-09
JP2021169535A (ja) 2021-10-28
AU2015320510B2 (en) 2019-11-21
CN112062727B (zh) 2023-10-31
RU2020101483A3 (es) 2020-05-12
US10457648B2 (en) 2019-10-29
JP2017529371A (ja) 2017-10-05
CN107001287A (zh) 2017-08-01
CA2962901A1 (en) 2016-03-31
CA3190507A1 (en) 2016-03-31
RU2732404C2 (ru) 2020-09-16
AU2015320510A1 (en) 2017-05-04
IL251313A0 (en) 2017-05-29
MX2019011513A (es) 2019-11-18
EP3626710B1 (en) 2022-02-16
RU2017114035A (ru) 2018-10-26
CN112062727A (zh) 2020-12-11
BR112017005931A2 (pt) 2017-12-19
IL251313B (en) 2019-08-29
RU2020101483A (ru) 2020-03-13
BR112017005931B1 (pt) 2024-04-30
IL267756B (en) 2020-06-30
US10870626B2 (en) 2020-12-22
JP2020059762A (ja) 2020-04-16
EP3197875A1 (en) 2017-08-02
PL3197875T3 (pl) 2020-03-31
EP3197875B1 (en) 2019-08-14
JP6676043B2 (ja) 2020-04-08
MX2017003791A (es) 2017-08-02
CA2962901C (en) 2025-11-18
HRP20191943T1 (hr) 2020-01-10
IL267756A (en) 2019-08-29
MY188699A (en) 2021-12-23
KR102513869B1 (ko) 2023-03-23
RU2017114035A3 (es) 2019-04-22
KR20170063809A (ko) 2017-06-08
MX380718B (es) 2025-03-12
ZA201702769B (en) 2019-07-31
WO2016049414A1 (en) 2016-03-31
US20170247338A1 (en) 2017-08-31
JP6926254B2 (ja) 2021-08-25
MA51165A (fr) 2020-10-21
SG10201806450SA (en) 2018-09-27
MX368298B (es) 2019-09-27
ES2749100T3 (es) 2020-03-19
AR102088A1 (es) 2017-02-01
CN107001287B (zh) 2020-09-04
US20200010428A1 (en) 2020-01-09
SG11201702324QA (en) 2017-04-27
EP3626710A1 (en) 2020-03-25
RU2712224C2 (ru) 2020-01-27

Similar Documents

Publication Publication Date Title
AR124856A2 (es) Proceso para preparar un compuesto intermediario para la síntesis de compuestos de (ciclopentil[d]pirimidin-4-il)piperazina
CL2021000566A1 (es) Procesos para fabricar ácido 2-((3r,5r,6s)-5-(3-clorofenil)-6-(4-clorofenil)-1-((s)-1-(isopropilsulfonil)-3-metilbutan-2-il)-3-metil-2-oxopiperidin-3-il)acético, intermediarios y procesos para fabricar los intermediarios, formas cristalinas del compuesto y los intermediarios. (divisional de la solicitud no. 2015003589)
MY188447A (en) Indazole compounds as fger kinase inhibitor, preparation and use thereof
LT3442980T (lt) Heterocikliniai junginiai, kaip ret kinazės inhibitoriai
BR112016025132A2 (pt) compostos polifluorados agindo como inibidores de tirosina quinase de bruton
MX378288B (es) Inhibidores de pirimidina del fgfr4.
MX374729B (es) Compuestos de heteroarilo o arilo biciclicos fusionados y su uso como inhibidores irak4.
IL247901A0 (en) Additional salts of (s)-2-(1-(6-amino-5-cyanopyrimidine-4-ylamino)ethyl)-4-oxo-3-phenyl-3,4-dihydropyrrolo[1,2-f][1 ,2,4]triazine-5-carbonitrile
EA201790395A1 (ru) Производные аминотриазина, подходящие для применения в качестве соединений-ингибиторов tank-связывающей киназы
MX2016000143A (es) Compuestos triciclicos fusionados de urea como inhibidores de raf quinasa y/o dimero de raf quinasa.
CL2014001765A1 (es) Proceso para la fabricacion de 1-[2-(2,4-dimetilfenilsulfanil)fenil]piperazina.
MX2019013645A (es) Inhibidores de quinasa y usos de los mismos.
MX2016015565A (es) Ciertos inhibidores de la proteina quinasa.
MX388606B (es) Sales del inhibidor fosfoinositida 3-cinasa (pi3k) y procesos para su preparacion.
DK3209647T3 (da) Krystallinske former af 5-chlor-n4-[-2-(dimethylphosphoryl) phenyl]-n2-{2-methoxy-4-[4-(4-methylpiperazin-1-yl) piperidin-1-yl]pyrimidin-2,4-diamin
DK3259289T3 (da) Fremgangsmåde til at fremstille inhiberet stivelse med forbedret forrådsopbevaringsstabilitet
CL2015002309A1 (es) Proceso de fabricacion de vortioxetina.
CL2016001172A1 (es) Nuevos inhibidores de dgat2.
MX374555B (es) Derivados de pirimidina como inhibidores de tirosina cinasa de bruton (btk) y usos de los mismos.
EA201790939A1 (ru) ТРИАЗОЛО[4,5-d]ПИРИМИДИНЫ В КАЧЕСТВЕ АГОНИСТОВ КАННАБИНОИДНЫХ РЕЦЕПТОРОВ ТИПА 2
EP3448852A4 (en) NOVEL HETEROCYCLIC COMPOUNDS AS INHIBITORS OF TYROSINE KINASE BCR-ABL
BR112017008481A2 (pt) composto antimicótico
BR112016029510A2 (pt) métodos para a preparação de um composto, e, composto intermediário.
CR20140560A (es) Formas y formulaciones de un compuesto de pirimidinilciclopentano, composiciones y metodos de este
LT3552017T (lt) Junginiai, naudotini kaip ripk1 inhibitoriai

Legal Events

Date Code Title Description
FB Suspension of granting procedure